![](https://webarchive.library.unt.edu/eot2008/20090116091514im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090116091514im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090116091514im_/http://www.cancer.gov/images/spacer.gif)
| Sustancia en estudio para el tratamiento de cáncer. Se elabora al enlazar el factor de necrosis tumoral (FNT) con un péptido. El péptido se une a los vasos sanguíneos del tumor y el FNT los daña. Es un tipo de modificador de la respuesta biológica. También se llama NGR-TNF. |
![](https://webarchive.library.unt.edu/eot2008/20090116091514im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090116091514im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090116091514im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090116091514im_/http://www.cancer.gov/images/spacer.gif) |